Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.
NCT00777673
Unknown
The purpose of this study is to determine how well this combination of chemotherapy drugs works with bevacizumab in eliminating primary tumor in the breast prior to surgery(pathological complete response or pCR in the breast). Bevacizumab is a drug that works by blocking new blood vessel formation by the tumor cells. Giving chemotherapy and bevacizumab before surgery may allow for lesser amount of breast tissue to be removed. To be able to predict in the future which patients are more likely to... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/03/2013
Locations: University of Tennessee Cancer Institute, Memphis, Tennessee +2 locations
Conditions: Breast Cancer
Register for Updates
Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes
NCT00509288
Completed
Background: * Human peripheral blood lymphocytes have been engineered to express a T-cell receptor (TCR) that recognizes a blood type,HLA-A 0201 (human leukocyte antigen) derived from the gp100 protein. A retroviral vector was constructed that can deliver the T-cell receptor (TCR) to cells. * Patients' cells will be converted into cells able to recognize and fight melanoma tumors. Objectives: * To determine whether TCR-engineered lymphocytes can be put in cells removed from patients' tumors o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2012
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Melanoma, Skin Cancer
Register for Updates
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
NCT00001832
Completed
This experiment will test the safety and effectiveness of a treatment for melanoma in which certain lymphocytes (a type of white blood cell) are taken from the patient, grown in the laboratory, and returned after the patient's immune system has been weakened with immune-suppressing drugs. Some patients will also receive interleukin-2 (IL-2), a drug that may enhance the activity of the re-infused lymphocytes. Patients with metastatic melanoma (melanoma whose tumor has spread) who have been treat... Read More
Gender:
ALL
Ages:
7 years and above
Trial Updated:
12/19/2012
Locations: National Cancer Institute (NCI), Bethesda, Maryland
Conditions: Melanoma, Neoplasm Metastasis
Register for Updates
Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer
NCT00003352
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy consisting of doxorubicin, cyclophosphamide, and docetaxel in treating women with stage IIIB or stage IV breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/10/2012
Locations: Baptist Medical Center - Birmingham, Birmingham, Alabama +165 locations
Conditions: Breast Cancer
Register for Updates
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
NCT00005641
Terminated
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Eliminating the T cells from the donor cells before transplanting them may prevent this from happening. PURPOSE: Phase II trial to study the effectiveness of T cell removal to prevent graft-versus-host disease in patients who are unde... Read More
Gender:
ALL
Ages:
Between 15 years and 60 years
Trial Updated:
12/10/2012
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Register for Updates
Ph II CHOP+Velcade in Mediastinal LBCL
NCT00361621
Terminated
The main purpose of this study is to begin to collect information and try to learn whether or not VELCADE, when added to standard chemotherapy with CHOP/Rituxan, works in treating patients mediastinal large B-cell lymphoma. Recent research has shown that this type of lymphoma shares features with Hodgkin's lymphoma, including the importance of a particular pathway in the tumor cells called the NF-kB pathway. VELCADE works in part by blocking this pathway.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/30/2012
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Non-Hodgkin's Lymphoma
Register for Updates
EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT00636155
Terminated
The purpose of this research study is to see if the investigational drug EL625, when combined with traditional chemotherapy (rituximab, fludarabine, and cyclophosphamide), is effective in Persistent Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2012
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Lymphoma, Small Lymphocytic, Leukemia, Lymphocytic, Chronic
Register for Updates
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor
NCT00003211
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy and radiation therapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy or radiation therapy and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy with topotecan, cyclophosphamide, cisplatin, and vincristine plus radiation therapy and peripheral stem cell transplant... Read More
Gender:
ALL
Ages:
Between 3 years and 20 years
Trial Updated:
11/06/2012
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee +3 locations
Conditions: Brain and Central Nervous System Tumors
Register for Updates
Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
NCT00136084
Completed
The purpose of this study is to compare the effectiveness of two multi-agent chemotherapy regimens using different dosages of cytarabine to eliminate all detectable leukemia.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
11/02/2012
Locations: Stanford University Medical Center, Palo Alto, California +7 locations
Conditions: Leukemia, Myelocytic, Acute
Register for Updates
Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma
NCT00000801
Completed
To estimate the response rate, overall and disease-free survival, toxicities, factors associated with outcome, and effect on quality of life in patients with AIDS-related primary CNS lymphoma treated with CHOD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) plus filgrastim (granulocyte-colony stimulating factor; G-CSF) and external beam irradiation. To determine other clinical markers present in this patient population. Combined modality therapy may prove of benefit for patients... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
10/31/2012
Locations: San Francisco AIDS Clinic / San Francisco Gen Hosp, San Francisco, California +6 locations
Conditions: Lymphoma, Non-Hodgkin, HIV Infections
Register for Updates
Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis
NCT01047072
Withdrawn
The purpose of the study is to see how well reduced intensity conditioning followed by a stem cell transplant from a donor (allogeneic) works in treating patients with severe systemic sclerosis. In an allogeneic stem cell transplant procedure, stem cells are taken from a healthy donor and transplanted into the patient. Stem cells can be donated by a family member or an unrelated donor who is a complete tissue type match.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/29/2012
Locations: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Systemic Scleroderma
Register for Updates
Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer
NCT00091611
Terminated
Background: * Some patients with advanced kidney cancer have immune cells that can recognize and kill their cancer, but the cells are not active enough or numerous enough to accomplish this on their own. * In recent studies of patients with advanced melanoma, some patients given special tumor-fighting cells (cells taken from the patient's tumor cells and grown in the laboratory) showed some anti-tumor response. Objectives: -To determine whether special tumor-fighting cells taken from the pati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/25/2012
Locations: National Cancer Institute (NCI), Bethesda, Maryland
Conditions: Kidney Neoplasms
Register for Updates